New publication about Modern Predictive Models for Recurrence and Progression in Patients treated with BLC

Oslo, Norway, September 16, 2026: Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces the publication of a new approach to outcome modeling in patients with bladder cancer that undergo a blue light cystoscopy (BLC^®) in the peer-reviewed journal Urologic Oncology this week. 

An abstract of this study was first presented at the AUA congress in 2025.The article titled “Performance of the EORTC and CUETO Risk Prediction Models in Contemporary Patients Undergoing Transurethral Resection of Bladder Tumor with Blue Light Cystoscopy,” by Boris Gershman, Harvard University, Beth Israel Deaconess Medical Center, describes new modelling for forecasting outcomes, using data from Photocure’s Blue Light Cystoscopy patient registry in the U.S.

The analysis included 899 patients with non-muscle invasive bladder cancer (NMIBC) who underwent transurethral resection of bladder tumor (TURBT) using BLC. The study found that the established EORTC and CUETO risk models had limited ability to accurately predict which patients would experience cancer recurrence or progression. In particular, the EORTC model tended to predict worse outcomes than were actually observed among patients in the BLC Registry.

The findings suggest that risk models developed using patients treated many years ago may not accurately reflect outcomes for patients receiving contemporary bladder cancer care. They highlight the need for updated prediction tools based on more recent patient populations and current treatment practices. Photocure’s Blue Light Cystoscopy Registry provides a large, contemporary U.S. dataset that can help support the development of these next-generation models.

Dr. Boris Gershman, principal author of the study, commented: “Accurate prediction of recurrence and progression risk is essential for the management of non-muscle invasive bladder cancer. However, the established EORTC and CUETO risk models performed poorly in predicting these outcomes among contemporary patients undergoing TURBT with blue light cystoscopy. We therefore used the multi-institutional Blue Light Cystoscopy Registry to develop modern predictive models for recurrence and progression in patients treated with BLC. These new models reflect contemporary treatment practices and have the potential to support more personalized, risk-adapted management of NMIBC.”

Read the full publication here: https://pubmed.ncbi.nlm.nih.gov/42744708